Importantly, MYC overexpression strongly reduced the efficacy of AZD8055 and everolimus, resulting in shortened mammary tumor–specific survival compared with the mTORi-treated cohort harboring MDA-MB-468 without MYC overexpression (Fig. 6, C and D). The gene discussed is MYC; the disease is breast cancer.